The discrepancies between human microglial signatures and their mouse counterparts could be explained by the fact that human brain samples usually represent a terminal stage of AD with amyloid and tau pathology, as well as extensive neuronal loss, while mouse models might just recapitulate either earlier stages of the disease characterized by Aβ accumulation or frontotemporal dementia–like tauopathy without amyloidosis (Alsema et al., 2020; Masuda et al., 2020; Boche and Gordon, 2021; Chen and Colonna, 2021; Provenzano et al., 2021). Here, MAPT is linked to amyloidosis.